» Articles » PMID: 38816064

Predictors for Severe Persisting Pain in Rheumatoid Arthritis Are Associated with Pain Origin and Appraisal of Pain

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2024 May 30
PMID 38816064
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To determine the proportion of patients with rheumatoid arthritis (RA) with severe persisting pain and to identify predictive factors despite treatment-controlled disease activity.

Methods: This prospective multicentre study included outpatients with RA scheduled for escalation of anti-inflammatory treatment due to active disease and severe pain (Disease Activity Score 28 (DAS28)>3.2 and Visual Analogue Scale (VAS)>50). At week 24, patients were stratified into reference group (DAS28 improvement>1.2 or DAS28≤3.2 and VAS pain score<50), non-responders (DAS28 improvement≤1.2 and DAS28>3.2, regardless of VAS pain score) and persisting pain group (DAS28 improvement>1.2 or DAS28≤3.2 and VAS pain score≥50). The former two subgroups ended the study at week 24. The latter continued until week 48. Demographic data, DAS28-C reactive protein, VAS for pain, painDETECT Questionnaire (PD-Q) to identify neuropathic pain (NeP) and the Pain Catastrophising Scale were assessed and tested for relation to persisting pain.

Results: Of 567 patients, 337 (59.4%) were classified as reference group, 102 (18.0%) as non-responders and 128 (22.6%) as patients with persisting pain. 21 (8.8%) responders, 28 (35.0%) non-responders and 27 (26.5%) persisting pain patients tested positive for NeP at week 24. Pain catastrophising (p=0.002) and number of tender joints (p=0.004) were positively associated with persisting pain at week 24. Baseline PD-Q was not related to subsequent persisting pain.

Conclusions: Persisting and non-nociceptive pain occur frequently in RA. Besides the potential involvement of NeP, pain catastrophising and a higher number of tender joints coincide with persisting pain.

Citing Articles

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study.

Taylor P, Fakhouri W, Ogwu S, Haladyj E, de la Torre I, Fautrel B Rheumatol Ther. 2024; 12(1):109-122.

PMID: 39688792 PMC: 11751266. DOI: 10.1007/s40744-024-00732-8.


Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons.

Vazquez E, Richter F, Natura G, Konig C, Eitner A, Schaible H Int J Mol Sci. 2024; 25(22).

PMID: 39596013 PMC: 11593535. DOI: 10.3390/ijms252211943.


Pain management in people with inflammatory arthritis: British Society for Rheumatology guideline scope.

Scott I, Babatunde O, Barker C, Beesley R, Beesley R, Birkinshaw H Rheumatol Adv Pract. 2024; 8(4):rkae128.

PMID: 39563967 PMC: 11573413. DOI: 10.1093/rap/rkae128.

References
1.
Dougados M, Brault Y, Logeart I, van der Heijde D, Gossec L, Kvien T . Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Res Ther. 2012; 14(3):R129. PMC: 3446510. DOI: 10.1186/ar3859. View

2.
Taylor P, Lee Y, Fleischmann R, Takeuchi T, Perkins E, Fautrel B . Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. J Clin Med. 2019; 8(6). PMC: 6617097. DOI: 10.3390/jcm8060831. View

3.
Koop S, Ten Klooster P, Vonkeman H, Steunebrink L, van de Laar M . Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis. Arthritis Res Ther. 2015; 17:237. PMC: 4558794. DOI: 10.1186/s13075-015-0761-8. View

4.
Ahmed S, Magan T, Vargas M, Harrison A, Sofat N . Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting. J Pain Res. 2014; 7:579-88. PMC: 4207578. DOI: 10.2147/JPR.S69011. View

5.
Campbell J, Meyer R . Mechanisms of neuropathic pain. Neuron. 2006; 52(1):77-92. PMC: 1810425. DOI: 10.1016/j.neuron.2006.09.021. View